[
  {
    "ts": "2025-12-16T03:46:07+00:00",
    "headline": "Scotiabank Remains Bullish on Eli Lilly and Company (LLY)",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on December 12, Scotiabank analyst Louise Chen reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) and set a price target of $1,165.00. In another development, Eli Lilly and Company (NYSE:LLY) announced on […]",
    "url": "https://finance.yahoo.com/news/scotiabank-remains-bullish-eli-lilly-034607161.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "a2bc9ae1-3b7b-3433-82c5-8fe5c341ce11",
      "content": {
        "id": "a2bc9ae1-3b7b-3433-82c5-8fe5c341ce11",
        "contentType": "STORY",
        "title": "Scotiabank Remains Bullish on Eli Lilly and Company (LLY)",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on December 12, Scotiabank analyst Louise Chen reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) and set a price target of $1,165.00. In another development, Eli Lilly and Company (NYSE:LLY) announced on […]",
        "pubDate": "2025-12-16T03:46:07Z",
        "displayTime": "2025-12-16T03:46:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Eli Lilly’s Mounjaro Added to China’s National Health Insurance for Diabetes",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aY42asq7dEA24eM0JX3IQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8359URliL1_uJRGx4OlSUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/scotiabank-remains-bullish-eli-lilly-034607161.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/scotiabank-remains-bullish-eli-lilly-034607161.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T10:35:00+00:00",
    "headline": "Where Will Eli Lilly Be in 10 Years?",
    "summary": "In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today.",
    "url": "https://www.fool.com/investing/2025/12/16/where-will-eli-lilly-be-in-10-years/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "2d48de93-d589-3816-a6d9-be7434f1862c",
      "content": {
        "id": "2d48de93-d589-3816-a6d9-be7434f1862c",
        "contentType": "STORY",
        "title": "Where Will Eli Lilly Be in 10 Years?",
        "description": "",
        "summary": "In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today.",
        "pubDate": "2025-12-16T10:35:00Z",
        "displayTime": "2025-12-16T10:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/13341a0633c66a604c3785b607545100",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "An investor looking at trends on a computer.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KI0PlRL6IBkslGzrLCmZjQ--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/13341a0633c66a604c3785b607545100.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/THwCQC5wM3bDnLegz1hDPA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/13341a0633c66a604c3785b607545100.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/16/where-will-eli-lilly-be-in-10-years/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/where-eli-lilly-10-years-103500804.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T13:30:00+00:00",
    "headline": "Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing",
    "summary": "BOSTON, December 16, 2025--Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs that provide employers with transparent, predictable access to obesity management medications from Eli Lilly and Company (Lilly) and Novo Nordisk (Novo), helping organizations offer comprehensive, wraparound care while controlling costs.",
    "url": "https://finance.yahoo.com/news/form-health-simplifies-glp-1-133000444.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "04fb9e80-d6ea-377c-a839-3dcef80dfb5a",
      "content": {
        "id": "04fb9e80-d6ea-377c-a839-3dcef80dfb5a",
        "contentType": "STORY",
        "title": "Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing",
        "description": "",
        "summary": "BOSTON, December 16, 2025--Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs that provide employers with transparent, predictable access to obesity management medications from Eli Lilly and Company (Lilly) and Novo Nordisk (Novo), helping organizations offer comprehensive, wraparound care while controlling costs.",
        "pubDate": "2025-12-16T13:30:00Z",
        "displayTime": "2025-12-16T13:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/5cdd0cdeae8b7ecf7c57172b8aae2904",
          "originalWidth": 782,
          "originalHeight": 271,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qRBj_VBVg5b9bgfVm6QQWQ--~B/aD0yNzE7dz03ODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5cdd0cdeae8b7ecf7c57172b8aae2904.cf.webp",
              "width": 782,
              "height": 271,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xBOOX3F2cDgEPINax6H3iA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5cdd0cdeae8b7ecf7c57172b8aae2904.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/form-health-simplifies-glp-1-133000444.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/form-health-simplifies-glp-1-133000444.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T16:50:00+00:00",
    "headline": "Is Eli Lilly a Buy Before 2026?",
    "summary": "Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio.",
    "url": "https://www.fool.com/investing/2025/12/16/is-eli-lilly-a-buy-before-2026/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "0bcf0390-bd98-33a6-88ea-100bc2a4f0f9",
      "content": {
        "id": "0bcf0390-bd98-33a6-88ea-100bc2a4f0f9",
        "contentType": "STORY",
        "title": "Is Eli Lilly a Buy Before 2026?",
        "description": "",
        "summary": "Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio.",
        "pubDate": "2025-12-16T16:50:00Z",
        "displayTime": "2025-12-16T16:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/fc95fa2cf9398bb604b15ceb3757e17b",
          "originalWidth": 1200,
          "originalHeight": 633,
          "caption": "Three scientists working in a lab, one of them studying a tablet and taking notes on paper.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/x8kk_XRJdjgmKlOWsZFvdg--~B/aD02MzM7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/fc95fa2cf9398bb604b15ceb3757e17b.cf.webp",
              "width": 1200,
              "height": 633,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cEr6O351HK9NCvCPFvqDmA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/fc95fa2cf9398bb604b15ceb3757e17b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/16/is-eli-lilly-a-buy-before-2026/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-buy-2026-165000329.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T16:07:23+00:00",
    "headline": "Will FDA Approval of an In‑House Teriparatide Pen Reshape Amphastar Pharmaceuticals' (AMPH) Narrative?",
    "summary": "In December 2025, Amphastar Pharmaceuticals announced that the FDA approved its abbreviated new drug application for a teriparatide injection prefilled pen, deemed bioequivalent and therapeutically equivalent to Eli Lilly’s FORTEO, with plans to launch the product in the US$585.0 million U.S. market by late 2025. A distinctive aspect of this approval is that Amphastar will manufacture the teriparatide product entirely in-house at its U.S. facility, which could reinforce supply reliability...",
    "url": "https://finance.yahoo.com/news/fda-approval-house-teriparatide-pen-160723541.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "58d90027-408b-3579-bb4b-6051663d3267",
      "content": {
        "id": "58d90027-408b-3579-bb4b-6051663d3267",
        "contentType": "STORY",
        "title": "Will FDA Approval of an In‑House Teriparatide Pen Reshape Amphastar Pharmaceuticals' (AMPH) Narrative?",
        "description": "",
        "summary": "In December 2025, Amphastar Pharmaceuticals announced that the FDA approved its abbreviated new drug application for a teriparatide injection prefilled pen, deemed bioequivalent and therapeutically equivalent to Eli Lilly’s FORTEO, with plans to launch the product in the US$585.0 million U.S. market by late 2025. A distinctive aspect of this approval is that Amphastar will manufacture the teriparatide product entirely in-house at its U.S. facility, which could reinforce supply reliability...",
        "pubDate": "2025-12-16T16:07:23Z",
        "displayTime": "2025-12-16T16:07:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pVOKMAerbRsXv56pHka6Lw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmyGBi4taxQExvvwka_9KQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-approval-house-teriparatide-pen-160723541.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-approval-house-teriparatide-pen-160723541.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMPH"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T15:00:00+00:00",
    "headline": "Lilly to participate in J.P. Morgan Healthcare Conference",
    "summary": "Eli Lilly and Company (NYSE: LLY) will participate in the 44th Annual J.P. Morgan Healthcare Conference, Jan. 12-15, 2025. David A. Ricks, Lilly chair and CEO, will take part in a fireside chat on Tuesday Jan. 13 at 5:15 p.m., Eastern time.",
    "url": "https://finance.yahoo.com/news/lilly-participate-j-p-morgan-150000346.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "47efcd9b-bd4d-3ca1-aeaa-8d0202be12c9",
      "content": {
        "id": "47efcd9b-bd4d-3ca1-aeaa-8d0202be12c9",
        "contentType": "STORY",
        "title": "Lilly to participate in J.P. Morgan Healthcare Conference",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) will participate in the 44th Annual J.P. Morgan Healthcare Conference, Jan. 12-15, 2025. David A. Ricks, Lilly chair and CEO, will take part in a fireside chat on Tuesday Jan. 13 at 5:15 p.m., Eastern time.",
        "pubDate": "2025-12-16T15:00:00Z",
        "displayTime": "2025-12-16T15:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-participate-j-p-morgan-150000346.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-participate-j-p-morgan-150000346.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T14:44:00+00:00",
    "headline": "Eli Lilly or Merck: Where Should Investors Put Their Money?",
    "summary": "LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.",
    "url": "https://finance.yahoo.com/news/eli-lilly-merck-where-investors-144400604.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "9e7fdf89-8ae6-3f5b-97b7-50b01321fd14",
      "content": {
        "id": "9e7fdf89-8ae6-3f5b-97b7-50b01321fd14",
        "contentType": "STORY",
        "title": "Eli Lilly or Merck: Where Should Investors Put Their Money?",
        "description": "",
        "summary": "LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.",
        "pubDate": "2025-12-16T14:44:00Z",
        "displayTime": "2025-12-16T14:44:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A9LQHlDmqgPJbKsotfjd8w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5.ym16dSp_UIlCHMRMZUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-merck-where-investors-144400604.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-merck-where-investors-144400604.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T14:23:00+00:00",
    "headline": "5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026",
    "summary": "MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors",
    "url": "https://finance.yahoo.com/news/5-high-risk-high-reward-142300115.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "bbaec809-3915-3c1f-b268-95bdcfcb0b76",
      "content": {
        "id": "bbaec809-3915-3c1f-b268-95bdcfcb0b76",
        "contentType": "STORY",
        "title": "5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026",
        "description": "",
        "summary": "MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors",
        "pubDate": "2025-12-16T14:23:00Z",
        "displayTime": "2025-12-16T14:23:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ffSS19YaoL36xXdlr0Ip4A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mJhhM1.2_VWzkATXxZYL_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-high-risk-high-reward-142300115.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-high-risk-high-reward-142300115.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T14:17:00+00:00",
    "headline": "3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most",
    "summary": "Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.",
    "url": "https://www.marketbeat.com/stock-ideas/3-healthcare-giants-just-raised-dividendsheres-who-pays-the-most/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "f693d6f5-2b2d-3ba9-8423-6620eac02a6a",
      "content": {
        "id": "f693d6f5-2b2d-3ba9-8423-6620eac02a6a",
        "contentType": "STORY",
        "title": "3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most",
        "description": "",
        "summary": "Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.",
        "pubDate": "2025-12-16T14:17:00Z",
        "displayTime": "2025-12-16T14:17:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/9fee6a58a220fb560af7cd812a39b361",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Stacks of gold coins forming an upward arrow beside a lab beaker and heart-rate icon.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n1X4uebG0cR05r1lyiRQEg--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/9fee6a58a220fb560af7cd812a39b361.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MykO9YhpdmTnvq_8P6dTyg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/9fee6a58a220fb560af7cd812a39b361.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/stock-ideas/3-healthcare-giants-just-raised-dividendsheres-who-pays-the-most/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-healthcare-giants-just-raised-141700337.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "SYK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T14:09:50+00:00",
    "headline": "Here Are Tuesday’s Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More",
    "summary": "Pre-Market Stock Futures: The futures are trading lower after what started as a bounce-back Monday turned into a reversal Monday, as the AI/Datacenter rotation trade continues to gather steam during the last whole trading week of 2025. Stocks rallied Monday on the open as traders tried to inject some holiday spirit, but by 12 noon ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More",
    "url": "https://247wallst.com/investing/2025/12/16/here-are-tuesdays-top-wall-street-analyst-research-calls-allstate-chubb-ltd-eli-lilly-kla-corp-lockheed-martin-mongodb-roku-and-more/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "d4ddf80c-e471-311f-830c-c63dada2e28b",
      "content": {
        "id": "d4ddf80c-e471-311f-830c-c63dada2e28b",
        "contentType": "STORY",
        "title": "Here Are Tuesday’s Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More",
        "description": "",
        "summary": "Pre-Market Stock Futures: The futures are trading lower after what started as a bounce-back Monday turned into a reversal Monday, as the AI/Datacenter rotation trade continues to gather steam during the last whole trading week of 2025. Stocks rallied Monday on the open as traders tried to inject some holiday spirit, but by 12 noon ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More",
        "pubDate": "2025-12-16T14:09:50Z",
        "displayTime": "2025-12-16T14:09:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/74bc60924e76f984dbb62a4d8faf6ff8",
          "originalWidth": 1366,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/28SlD17sAW4WuYCLqrNyeg--~B/aD03Njg7dz0xMzY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/74bc60924e76f984dbb62a4d8faf6ff8.cf.webp",
              "width": 1366,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_WgxvwyvOnfgA_auAxWYuw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/74bc60924e76f984dbb62a4d8faf6ff8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/12/16/here-are-tuesdays-top-wall-street-analyst-research-calls-allstate-chubb-ltd-eli-lilly-kla-corp-lockheed-martin-mongodb-roku-and-more/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tuesday-top-wall-street-analyst-140950411.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DOC"
            },
            {
              "symbol": "MCHP"
            },
            {
              "symbol": "MCHPP"
            },
            {
              "symbol": "ROK"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "CGNX"
            },
            {
              "symbol": "TRV"
            },
            {
              "symbol": "ADP"
            },
            {
              "symbol": "ALL"
            },
            {
              "symbol": "ALL-PH"
            },
            {
              "symbol": "ALL-PI"
            },
            {
              "symbol": "ALL-PJ"
            },
            {
              "symbol": "MDB"
            },
            {
              "symbol": "TNDM"
            },
            {
              "symbol": "ROKU"
            },
            {
              "symbol": "FRPT"
            },
            {
              "symbol": "CB"
            },
            {
              "symbol": "ZBH"
            },
            {
              "symbol": "KLAC"
            },
            {
              "symbol": "JRVR"
            },
            {
              "symbol": "UBS"
            },
            {
              "symbol": "LMT"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T12:03:00+00:00",
    "headline": "Pfizer Adds to Its Big Bet on Weight Loss Drugs",
    "summary": "A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.",
    "url": "https://www.marketbeat.com/originals/pfizer-adds-to-its-big-bet-on-weight-loss-drugs/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "2a984f70-2f43-39e2-901b-38f4848d3dc4",
      "content": {
        "id": "2a984f70-2f43-39e2-901b-38f4848d3dc4",
        "contentType": "STORY",
        "title": "Pfizer Adds to Its Big Bet on Weight Loss Drugs",
        "description": "",
        "summary": "A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.",
        "pubDate": "2025-12-16T12:03:00Z",
        "displayTime": "2025-12-16T12:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/44fcc0338a641fcbb0eff1772200ab5e",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Pfizer-branded beaker filled with blue liquid in a bright, modern laboratory.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YqRsnX_YhH3igP6M4KHXrw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/44fcc0338a641fcbb0eff1772200ab5e.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CS049xxA5qcHmH7krl1BAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/44fcc0338a641fcbb0eff1772200ab5e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/originals/pfizer-adds-to-its-big-bet-on-weight-loss-drugs/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-adds-big-bet-weight-120300213.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T09:30:00+00:00",
    "headline": "China's new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms?",
    "summary": "Mainland China's 17 million Alzheimer's patients can, for the first time, pay less out of pocket for a costly drug touted as \"historic\" and \"the beginning of the end\" for the memory-robbing disease after Beijing launched a commercial insurance innovative drug list in an effort to make medicines more accessible and affordable. Leqembi, developed by Japan's Eisai and costing a mainland Chinese patient about US$28,400 a year, could see its price cut by half after it was added to the inaugural editi",
    "url": "https://finance.yahoo.com/news/chinas-drug-insurance-lifeline-patients-093000107.html",
    "source": "South China Morning Post",
    "provider": "yfinance",
    "raw": {
      "id": "00b1ef38-7f0c-3275-b283-9640b27770e5",
      "content": {
        "id": "00b1ef38-7f0c-3275-b283-9640b27770e5",
        "contentType": "STORY",
        "title": "China's new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms?",
        "description": "",
        "summary": "Mainland China's 17 million Alzheimer's patients can, for the first time, pay less out of pocket for a costly drug touted as \"historic\" and \"the beginning of the end\" for the memory-robbing disease after Beijing launched a commercial insurance innovative drug list in an effort to make medicines more accessible and affordable. Leqembi, developed by Japan's Eisai and costing a mainland Chinese patient about US$28,400 a year, could see its price cut by half after it was added to the inaugural editi",
        "pubDate": "2025-12-16T09:30:00Z",
        "displayTime": "2025-12-16T09:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/south_china_morning_post_us_228/837f6a6aef245cbbebfb9e245cd11b86",
          "originalWidth": 1999,
          "originalHeight": 1330,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0t1tswI9q1uIkNNt.XaKbQ--~B/aD0xMzMwO3c9MTk5OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/south_china_morning_post_us_228/837f6a6aef245cbbebfb9e245cd11b86.cf.webp",
              "width": 1999,
              "height": 1330,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/we3AnLQ3y1XZM4aRKIsx2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/south_china_morning_post_us_228/837f6a6aef245cbbebfb9e245cd11b86.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "South China Morning Post",
          "url": "https://www.scmp.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/chinas-drug-insurance-lifeline-patients-093000107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/chinas-drug-insurance-lifeline-patients-093000107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ESAIY"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]